17 reports

  • Bladder cancer therapeutics market in Americas
  • Bladder cancer therapeutics market in EMEA

Strength: ## Low; ## High F.

  • Bladder Cancer
  • Market Size
  • Bristol-Myers Squibb Company
  • Eli Lilly & Co.
  • Pfizer Inc.

Bladder Cancer KOL Interview – US A US KOL provides insight into the current treatment landscape for bladder cancer.

  • Bladder Cancer
  • Cancer
  • Pathology
  • United States
  • Market Size
  • KEY US METRICS (2025)
  • IO COMBINATION THERAPIES WILL ACCOUNT FOR NEARLY HALF OF TOTAL IO SALES BY 2025

Based on melanoma studies and what we know about bladder cancer, adding IDO## to PD-## does not substantially increase toxicity.

  • Bladder Cancer
  • United States
  • Market Size
  • Eli Lilly & Co.
  • Merck & Co., Inc.

However, NMIBCs are characterized by a high risk of recurrence, leading to a high disease burden and making bladder cancer one of the costliest malignancies to treat.

  • Bladder Cancer
  • European Union
  • Japan
  • United States
  • Market Size
  • BLADDER CANCER: KEY METRICS IN THE 7MM
  • EFFICACY OF TICE BCG IN CIS BLADDER CANCER

CANCER; ##(##): ##-##.

  • Bladder Cancer
  • United States
  • Market Size
  • Merck & Co., Inc.
  • OncoGenex Pharmaceuticals, Inc.

Bladder Cancer Phase ## Clinical Trials, 2016 ##.

  • Bladder Cancer
  • France
  • Germany
  • United States
  • Market Size
  • Table12: Bladder Cancer Treatment Drugs Import by Country in

In 1980s and 1990s, the incidence of bladder cancer per ##, ## populations was about one twentieth.

  • Bladder Cancer
  • China
  • Market Size
  • Bristol-Myers Squibb China Inc Ltd
  • Sanofi-Synthelabo Inc.
  • Table12: Bladder Cancer Treatment Drugs Import by Country in

In 1980s and 1990s, the incidence of bladder cancer per ##, ## populations was about one twentieth.

  • Bladder Cancer
  • China
  • Market Size
  • Bristol-Myers Squibb China Inc Ltd
  • Lilly Pharmaceutical China Inc

Bladder Cancer Phase ## Clinical Trials, 2016 ##.

  • Bladder Cancer
  • France
  • Germany
  • Italy
  • Market Size

Bladder Cancer Phase ## Clinical Trials, 2016 ##.

  • Bladder Cancer
  • Cancer
  • Pathology
  • Japan
  • Market Size

Bladder Cancer Phase ## Clinical Trials, 2016 ##.

  • Bladder Cancer
  • Cancer
  • Pathology
  • United States
  • Market Size

Bladder Cancer Phase ## Clinical Trials, 2016 ##.

  • Bladder Cancer
  • Cancer
  • Pathology
  • United Kingdom
  • Market Size

Bladder Cancer Phase ## Clinical Trials, 2016 ##.

  • Bladder Cancer
  • Cancer
  • Pathology
  • Italy
  • Market Size

Bladder Cancer Phase ## Clinical Trials, 2016 ##.

  • Bladder Cancer
  • Cancer
  • Pathology
  • France
  • Market Size

Bladder Cancer Phase ## Clinical Trials, 2016 ##.

  • Bladder Cancer
  • Cancer
  • Pathology
  • Germany
  • Market Size

Bladder Cancer Phase ## Clinical Trials, 2016 ##.

  • Bladder Cancer
  • Cancer
  • Pathology
  • Spain
  • Market Size
  • Timeline of Approvals/Estimated Approvals for Avelumab
  • Development of Avelumab Across Oncology Indications

ATEZOLIZUMAB WILL ALSO SEE SIGNIFICANT SALES IN BLADDER CANCER, WHERE IT WILL BE THE PD-(L)## INHIBITOR OF CHOICE.

  • Bladder Cancer
  • Immunotherapy
  • Pathology
  • Therapy
  • Market Size